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Background: Hepatocellular carcinoma (HCC) is a challenging malignancy of global importance, it is the third most
common cause of cancer-related mortality worldwide. In the last years the multikinase inhibitor sorafenib has been
used for advanced HCC, but some patients do not benefit from this therapy; thus, novel therapeutic options
based on molecular approaches are urgently needed. microRNAs are short non coding RNAs involved in several
physiological and pathological conditions including HCC and increasing evidence describes miRs as good tools for the
molecular targeted therapies in HCC. The purpose of this study was to identify novel approaches to sensitize the HCC
cells to sorafenib by microRNAs targeting urokinase-type plasminogen activator (uPA).
Methods: The miR-193a was validated as negative regulator of urokinase-type plasminogen activator (uPA) in 2 HCC
undifferentiated cell lines by transient transfection of miR and anti-miR molecules. The molecular interaction between
miR-193a and uPA mRNA target was verified by luciferase reporter assay. The miR-193a expression level was evaluated
by stem-loop real time PCR in tumoral tissues from 39 HCC patients. The HCC cells were co-treated with sorafenib and
miR-193a and the effects on cellular proliferation, apoptosis were tested. The effect of sorafenib on c-met expression
levels was assessed by western blotting.
Results: The miR-193a has resulted a negative regulator of uPA in both the HCC cell lines tested. The miR-193a
expression has resulted dysregulated in tumoral tissues from 39 HCC patients. We found miR-193a down-regulation
in HCC respect to peritumoral (PT) tissues and more in the cirrhotic HCCs than in non-cirrhotic ones. Transfection of
HA22T/VGH HCC cells with miR-193a decreased proliferation and increased apoptosis, and combined treatment with
miR-193a and sorafenib led to further proliferation inhibition.
Conclusions: Our results present new advances in the post-transcriptional miR-mediated mechanisms of uPA and they
suggest a new strategy to impair the aggressive behavior of HCC cells. Our findings could be helpful to explore novel
approaches for multi-target and multi-agent therapies of the HCC.
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Hepatocellular carcinoma (HCC) is one of the most le-
thal malignancies, it is the third most common cause of
cancer-related mortality worldwide. Surgical resection
and liver transplantation are first-line curative options for
patients with early stage HCC, as they confer 5-year sur-
vival rates of 70%. Locoregional therapies such as transar-
terial chemoembolization and radiofrequency ablation are* Correspondence: depetro@med.unibs.it
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reproduction in any medium, provided the orcare for patients not suitable for surgery [1-3]. In recent
years the multikinase inhibitor sorafenib has been used to
treat advanced HCCs improving the overall survival of
HCC patients from 7.9 months to 10.7 months and it is
the sole systemic drug that is proved to be effective in this
disease [4,5]. For this reason, efforts that focus on the
implementation of personalized medicine approaches in
HCC in the next years will be a challenge. It is well known
that microRNAs (miRs) control a wide range of physio-
logical and pathological processes, including cancer [6].
Dysregulation of miRs may play a relevant role in hepato-
carcinogenesis and HCC progression [7]. For example, thed. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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more than 50-70% of HCCs and this loss of miR-122 ex-
pression is correlated with poor prognosis and metastasis
of liver cancer [8]. In contrast, miR-21, miR-221 and miR-
224 are generally reported to be upregulated in HCC tis-
sues [9-11]. Several studies indicate that miRNAs expres-
sion may have clinical relevance as biomarkers for HCC
stratification, early diagnosis or the follow-up of patients
[12]. Additionally, studies showing that miRNAs them-
selves or anti-miRNA oligonucleotides can be successfully
used for in vitro and in vivo modulation of miRNA actions
have indicated significant potentials for molecular targeted
therapy [13,14]. Additional studies have shown that some
miRs may sensitize or improve the effects of the more
conventional therapies in HCC cells. For example, an
miR-122 mimetic alone or in combination with sorafenib
reduced the tumourigenic properties of HCC cells and
may therefore be a promising therapeutic regimen for liver
cancer [15]. Chemoresistance to cisplatin is a major limi-
tation of cisplatin-based chemotherapy in the clinic. In
HCC patients treated with cisplatin-based chemotherapy,
miR-199a-5p levels were significantly reduced; forced
expression of miR-199a-5p promoted the cisplatin-induced
inhibition of cell proliferation [16]. The resistance of
HCC cells to 5-FU is mediated by miR-193a-3p via
inhibition of the expression of serine/arginine-rich spli-
cing factor 2 (SRSF2) expression. In turn, SRSF2 prefer-
entially up-regulates the proapoptotic splicing form of
caspase 2 (CASP2L) and sensitizes HCC cells to 5-
FU. Forced changes of miR-193a-3p level were shown
to reverse the 5-FU sensitivity, in cell culture and in
nude mice [17]. It is well known that the serine pro-
tease urokinase type plasminogen activator (uPA) is a
responsive therapeutic target for HCC and others ma-
lignancies and its overexpression correlates with tumour
invasion and metastasis [18-22]. In this work, to study the
co-treatment of HCC cells with sorafenib and miRNAs
targeting uPA we have first validated the miR-193a-3p as a
negative regulator of uPA in HCC cells; furthermore, we
have tested the effects of miR-193a-3p in combination
with sorafenib.
Results
miR-193a negatively regulates uPA expression in HCC
derived cell lines
Before studying the co-treatment of the HCC cells with
sorafenib and miRNAs, we studied miRs that were pre-
dicted by bioinformatic tools to putatively regulate uPA
expression. We have previously predicted miR-193a to be
a negative regulator of uPA expression [23], among others.
There are two putative binding sites located at the 3′UTR
uPA mRNA (Figure 1A). Both sites, but in particular site 2
(nt 2220–2226 NCBI access number NM_002658), are
phylogenetically conserved across the species (Figure 1B).We transfected the HCC-derived cell line HA22T/
VGH with pre-miR-193a molecules and we found that the
uPA enzymatic activity was significantly inhibited in the
transfected cells compared with control cells (Figure 2A).
Conversely, the transfection of anti-miR-193a molecules
resulted in upregulation of uPA enzymatic activity and
protein expression, 48 h and 72 h after transfection
(Figure 2B). To determine whether miR-193a could dir-
ectly interact with 3′ UTR uPA mRNA we performed the
luciferase reporter assays. The entire 3′UTR uPA mRNA
cloned downstream to the luciferase CDS resulted in in-
hibition of luciferase activity when the construct (pGL4.71
uPA-3′ UTR S) was co-transfected with pre-miR-193a
(Figure 2C histogram 2). As shown in Figure 2D the
predicted binding site 2, cloned in another type of lu-
ciferase plasmid (pmiRGLO uPA S2), was directly rec-
ognized by miR-193a while the site 1 (pmiRGLO uPA S1)
was not. To understand whether the miR-193a may influ-
ence the malignant phenotype of the HA22T/VGH cells
we transfected the cells with pre-miR-193a or anti-miR-
193a and we assessed their effects on cellular prolifera-
tion. We observed a low decrease in cell proliferation
when transfecting pre-miR-193a molecules (up to 21%
at 72 h from transfection at 100 nM concentration,
Figure 2E) however we obtained an induction of pro-
liferation when transfecting anti-miR-193a molecules
(up to 23% at 72 h from transfection at 100 nM con-
centration; p < 0.01; Figure 2F). The validation of miR-
193a as negative regulator of uPA was extended to the
HCC cell line SKHep1C3. The transfection of pre-miR-
193a resulted in downregulation of uPA protein/enzymatic
activity (Figure 3A), while transfection of anti-miR-193a
(Figure 3B) up-regulated the level and activity of uPA.
As determined in the luciferase reporter assay (Figure 3C),
site 2 was directly bound by miR-193a whereas site 1 was
not recognized by miR-193a, as observed in the HA22T/
VGH cells.
miR-193a is downregulated in HCC biopsy specimens
The expression levels of mature miR-193a were assessed
by real time PCR. miR-193a resulted down-regulated in
HCC tissues from biopsy specimens of 39 HCC patients
(Additional file 1) with respect to their peritumoral (PT)
counterparts (average RQPT = 5.53 ± 0.93; average RQHCC =
3.27 ± 0.77 p < 0.05; R = (RQHCC/RQPT) 0.59) (RQ = rela-
tive quantification) (Figure 4A and Additional file 2 and
Additional file 3). We have stratified the cases on the basis
of presence or absence of cirrhosis as background liver
disease; for the class of non-cirrhotic HCCs (n = 14) we
observed an average RQPT = 6.6 ± 2, an average RQHCC =
4.3 ± 1.46 with a ratio (R = RQHCC/RQPT) value of 0.65
(Figure 4B and Additional file 3 and Additional file 4);
and for the class of cirrhotic HCCs (n = 25), the average
RQPT was 4.9 ± 0.94; the average RQHCC was 2.7 ± 0.88
AB
Figure 1 uPA putative binding sites for miR-193a located in the 3′-UTR mRNA and its phylogenetically conservation. (A) 3′-UTR uPA
mRNA displays two putative binding sites for miR-193a. (B) The complementarity between miR-193a and the putative uPA 3′-UTR target sites are
shown. The conserved bases of the putative miR-193a target sequence are also shown. hsa, Homo sapiens; ptr, P. troglodytes (chimpanzee); mmu,
M. musculus (mouse); rno, R. norvegicus (rat); cfa, C. familiaris (dog).
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files 3 and Additional file 4). We further stratified the
cirrhotic HCCs on the basis of the type of hepatitis
virus infections and for each sub-class we calculated
the average R (RQHCCn/RQPTn). We found that the
class of HCV (n = 10) presented the lowest average R
(R = 0.338) which was significantly different from the
expected value = 1, p < 0.01; the R values of the HBV
(n = 4), HBV +HCV (n = 4) and −/− (n = 4) classes were
1.29 ± 0.75; 0.645 ± 0.28 and 0.77 ± 0.11 respectively and
they did not significantly differ from 1 (Figure 4D). By
stratifying the non-cirrhotic HCCs on the basis of the
type of hepatitis virus infection we have found no ex-
pression variation (Additional file 5). Interestingly, when
we considered all the HCV patients (n = 15) with or with-
out cirrhosis the mean R value was 0.604 ± 0,14 which
was significantly different from the expected value = 1,
p = 0.0167 (Additional file 5).Effects of miR-193a ectopic expression and sorafenib on
the HCC cells
To study the effects of the co-treatment on the HCC
cells with miR-193a and sorafenib we have first of all
evaluated the effect of sorafenib on cellular proliferation.
The treatment of 4 HCC cell lines with sorafenib (5, 10,
15 μM concentration) for 3 days (24, 48 and 72 h) inhib-
ited proliferation (Figure 5A-D). The most sensitive
HCC cell line was HepG2 which had the highest per-
centage of inhibition of proliferation (72%) 72 h follow-
ing treatment with 15 μM of sorafenib (Figure 5A). It
is known that some microRNAs can improve the sensitiv-
ity of cancer cells to conventional drugs and chemothera-
peutic agents, for this reason we tested whether miR-193a
could increase the effect of sorafenib on HCC cells. We
treated HA22T/VGH ectopically expressing miR-193a with
sorafenib and monitored cell growth. The MTT assay data
showed that the growth of the HA22T/VGH cells was
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Figure 2 (See legend on next page.)
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Figure 2 Experimental validation of miR-193a as negative regulator of uPA in HA22T/VGH cells. (A) Enzymatic activity evaluated by
zymography after pre-miR-193a transfection in HA22T/VGH cells. Three experiments were performed; histograms represent the mean values, bars
are the SE. *p < 0.05; **p < 0.01 ***p < 0.001 versus Lipofectamine in a t-Test analysis for unpaired comparison. (B) anti-miR-193a transfection in HA22T/
VGH cells causes increase of uPA protein expression and its correspondent enzymatic activity. Three experiments were performed; histograms
represent the mean values, bars are the SE. *p < 0.05; **p < 0.01 ***p < 0.001 versus Lipofectamine in a t-Test analysis for unpaired comparison.
(C-F) Dual-luciferase reporter assay and cellular proliferation. (C) The 3′-UTR of uPA was cloned in the pGL4.71 reporter plasmid after the Renilla
luciferase CDS in sense (pGL4.71 uPA-3′ UTR-S) and antisense (pGL4.71 uPA-3′ UTR-AS) orientation. The constructs were cotransfected into
HA22T/VGH cells with 0, 25 and 50 nM miR-193a mimics. Luciferase activity was normalized relative to a simultaneosly transfected firefly
luciferase expression plasmid (pGL3). The construct pGL4.71 uPA-3′ UTR-S determined the inhibition of the luciferase activity, *p < 0.05; **p < 0.01
versus –miR-193a. (D) 30 nt-sequences containing the putative binding site 1 and 2 were cloned after the firefly luciferase CDS of the pmiRGLO
plasmids carrying also the Renilla luciferse gene. The 2 plasmids (pmiRGLO uPA S1, pmiRGLO uPA S2) were cotrasfected with 50 nM and
100 nM miR-193a mimics in HA22T/VGH cells. Site 2 resulted in the inhibition of the luciferase activity while site 1 did not, * p < 0.05 versus pmiRGLO.
(E-F) The transfection of pre-miR-193a and anti-miR-193a in HA22T/VGH cells led to a low level of proliferation inhibition and induction respectively.
The histograms represent the mean of three experiments; bars are the SE. *p < 0.05; **p < 0.01 versus HA22T/VGH.
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miR-193a and sorafenib (Figure 6A, B-E ). The fold change
increases (calculated by dividing the percentage of prolif-
eration inhibition of sorafenib +miR-193a cells and the
percentage of proliferation inhibition of the cells treated
with sorafenib alone) were between 2.3 and 2.6 both at
48 h and 72 h after transfection respectively (Figure 6A)
and 2.1 in the cotreated cells with 50 nM miR-193a and
15 μM sorafenib vs 50 nM negative control miRNA and
15 μM sorafenib (Figure 6C).
The quantification of TUNEL-positive SKHep1C3 cells
showed that miR-193a overexpression can induce HCC
cell apoptosis (Figure 6F, histogram n. 7), that transfec-
tion with 100 nM miR-23b or miR-193a and treatment
with 5 μM sorafenib increased the number of apoptotic
cells up to 1.89 and 1.95 fold respectively compared with
treatment with sorafenib alone (Figure 6F, histograms 6
and 8) and that the combined treatment of miR-23b and
sorafenib increased the number of apoptotic cells com-
pared with treatment with miR-23b alone. We chose also
miR-23b for this analysis because we previously reported
that miR-23b is a negative regulator of uPA and c-met in
SKHep1C3 cells and its ectopic expression negatively reg-
ulates properties related to cellular aggressiveness [23].
Sorafenib mediates c-met expression downregulation
To determine the relationship between the RTK c-met
copy number and the cellular proliferation after sorafe-
nib treatment, the c-met copy number was calculated in
the four HCC cell lines considered. Interestingly, there
was an inverse trend between the highest percentage of
obtained inhibition of proliferation after sorafenib treat-
ment and the c-met copy number (Figure 7A). The
HA22T/VGH cell line that displayed an intermediate
sensitivity to sorafenib and the most sensitive HepG2
cells were analyzed for c-met protein expression.
The tyrosine kinase c-met is synthesized as a 170-kDa
precursor protein that is further cleaved to form an α-
chain of 50 kDa linked by disulfide bonds with a 145-kDa β-chain. In the HA22T/VGH and in the HepG2
cells treated with sorafenib, the c-met precursor of
170 kDa resulted inhibited mainly after treatment with
10 and 15 μM of sorafenib at both 24 h and 48 h time
points and the c-met β chain of 145 kDa decreased
mainly at 15 μM sorafenib at the later time point (48 h)
(Figure 7B). The levels of p-c-met (Y1003) in HA22T/
VGH cells were inhibited at the 24 h time point both
the 170 kDa precursor protein and the 145-kDa β-chain;
this could reflect the c-met protein expression level. At
T = 48 h we have found a decrease of the precursor form
of 170 kDa of p-c-met after the treatment with 10 and
15 μM of sorafenib respect to control and 5 μM dose.
We have also detected a higher amount of the 145 kDa
form of p-c-met in the sorafenib treated cells compared
with the untreated cells. It is known that the phosphor-
ylation at the Y1003 plays a role in the ubiquitination of
the c-met and thus in its degradation [23]. All together
these observations indicate that the sorafenib might me-
diate the degradation of the c-met by favoring the ubi-
quitination and thus its degradation.
Discussion
It is well known that the uPA and the RTK c-met are
generally overexpressed in HCC. They are considered
negative prognostic factors and responsive therapeutic
targets for this type of cancer [20,24,25]. We have previ-
ously shown that miR-23b targets both uPA and c-met
expression in HCC cell lines and the ectopic overexpres-
sion of miR-23b reduces the malignant properties of the
cells [23]. Here, with the aim to increase the molecular
tools available to silence uPA we have studied the hsa-
miR-193a-3p previously predicted by us to target uPA
[23]. Our results clearly show that miR-193a negatively
regulates uPA in 2 HCC-derived cell lines. Other authors
have previously described uPA as a target of miR-193a-
3p in breast-cancer cell lines [26,27]. It is known that a
given miR may control the expression level of a gene in
some biological context (i.e. cells, tissues) but not in
5.    SKHep1C3 72h
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Figure 3 Experimental validation of miR-193a as negative regulator of uPA in SKHep1C3 cells. (A) pre-miR-193a transfections in SKHep1C3
cells inhibited uPA protein expression and the enzymatic activity. (B) Anti-miR-193a transfection in SKHep1C3 cells led to up-regulation of uPA
protein expression and the enzymatic activity up-regulation, *p < 0.05; **p < 0.01 versus Lipofectamine in a t-Test analysis for unpaired comparison.
(C) The dual luciferase assay shows that the site 2 was directly bound by miR-193a but the site 1 was not. pmiRGLO uPA S1 and pmiRGLO uPA
S2 are the luciferase constructs expressing the predicted 3′ UTR mRNA uPA binding site 1 and site 2. The pmiRGLO uPA AS1 and pmiRGLO uPA
AS2 are the constructs expressing the corresponding control antisense sequences, *p < 0.05 versus – miR-193a.
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in different cell lines is necessary. Because uPA levels are
generally higher in HCC tissues with respect to their ad-
jacent non-tumoural counterparts, we quantified the miR-
193a expression in tissues from biopsy specimens of donor
patients. In agreement with the hypothesis that miR-193a
inhibits uPA expression, mature miR-193a generally re-
sulted down-regulated in HCC tissues compared with thePT counterparts (R = 0.59; p < 0.05). These novel results
support the idea that miR-193a would target uPA not only
in HCC cell lines, but also in human liver tissue making
miR-193a a promising tool for down-regulating uPA ex-
pression levels. Interestingly, when considering the critical
importance of the presence or absence of hepatic cirrhosis
for the classification and the subdivision of the patients,
we observed a lower and more statistically significant level
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Figure 4 miR-193a expression analysis by Real-Time PCR in tumoral tissues from biopsy samples of HCC patients. (A) The level of mature
miR-193a is generally down-regulated in HCC compared with the corresponding PT tissues average RQPT = 5.53 ± 0.93, RQHCC = 3.27 ± 0.77; p < 0.05.
(B)miR-193a expression level in HCCs developed in non-cirrhotic and (C) cirrhotic liver. (D) Cirrhotic HCCs stratified on the basis of the type of hepatitis
viral infections. The class of HCV showed the lowest average R (average R = 0.338; p < 0.01 in a t-Test analysis for single group mean with
expected value = 1).
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pared with those that were non-cirrhotic (R = 0.65). Fur-
thermore, cirrhotic HCCs with HCV infection showed a
very low miR-193a expression level compared with PT
tissues (R = 0.338), but HBV, HBV +HCV and −/− did not
display any substantial miR-193a expression changes. We
are aware that the classification of the cirrhotic HCCs on
the basis of the type of hepatitis virus infection is made on
small sample size; thus this analysis will be extended to a
larger number of HCC cases. It is known that miRs can
alter their expression as a result of viral infection or in
particular pathological and stress conditions [28]. Notably,
hepatic cirrhosis decreased the expression level of miR-
193a (RQPTnc = 6.6; RQPTc = 4.9), a further decrease in
miR-193a levels was observed as a result of hepatocyte
transformation (RQHCCnc = 4.3; RQHCCc = 2.7). It is notuncommon that miRs can vary during the different stages
from liver healthy tissues to pathological hepatic lesions
that often precede the onset of HCC. In a previous report
we found that miR-24, miR-27a and miR-21 were dif-
ferentially expressed in cirrhotic/non-cirrhotic HCCs
[29]. Therefore, to hypothesize a putative role of miR-193a
as marker of stage progression it will be necessary to
evaluate its expression also in the condition of healthy and
unhealthy liver tissues (i.e., chronic hepatitis, steatosis).
It is a shared opinion that novel therapies for HCC
based also on molecularly targeted-therapy are urgently
needed. The sorafenib is an oral multikinase inhibitor
that targets Raf, VEGFR-2/3, PDGFR-β, Flt3 and c-kit.
It is used to treat the advanced HCC, but some patients
do not benefit from this therapy [5]. One of the main


































































































Figure 5 Effects of the sorafenib treatment on HCC cell lines. The HepG2, HA22T/VGH, SKHep1C3 and HuH6 cell lines were treated with
sorafenib (5, 10, 15 μM concentration) for 3 days (24, 48 and 72 h). The proliferation was inhibited in a dose-dependent manner in all the cell lines
considered (A-D). The most responsive HCC cell line was HepG2 (the highest percentage of the inhibition of proliferation was 72% with 15 μM of
sorafenib at T = 72 h) (A). Statistical significance was determined by one way ANOVA with Bonferroni correction *p < 0.05; ***p < 0.001.
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tion of alternative pathways [30]. An effective method
to sensitize the cancer cells to sorafenib or the use of
combined therapies are ambitious objectives to pursue. In
fact, miR-193a transfection decreased proliferation and in-
creased apoptosis and combined treatment of HCC cells
with miR-193a and sorafenib showed additional effects
in terms of cellular proliferation inhibition. The data ob-
tained from the c-met copy number assay indicate an in-
verse trend between the number of c-met copies and the
degree of reduced proliferation obtained following sorafe-
nib treatment in the four HCC cell lines. It is known that
c-met amplification negatively affects the survival of surgi-
cal resected non-small cell lung patients and the c-met
gene copy number was linked to resistance to the tyrosine
kinase inhibitor gefitinib in non-small cell lung cancer
patients [31,32]. The fact that c-met copy number (and
reasonably the c-met expression level) may have a role in
the efficacy of sorafenib, at least in vitro, led us to analyze
the expression level of c-met protein following sorafenib
treatments in cells. The c-met protein levels were inhib-
ited in treated HA22T/VGH and HepG2 cells and this
may indicate, for the first time in the present work, a dir-
ect or an indirect role of sorafenib in controlling c-met
expression. We further observed that the amount of the
phosphorylated form (Y1003) of the c-met β chain of
145 kDa was increased in the treated HA22T/VGH cells
at 48 h time point following treatment. The tyrosineresidue (Y1003) located in the juxtamembrane domain,
upon phosphorylation, binds to the E3-ubiquitin ligase Cbl,
which promotes receptor ubiquitination, endocytosis and
degradation [33]. We therefore surmise that sorafenib may
decrease the expression of c-met by promoting its degrad-
ation at least at the later time points following the treat-
ment, and this could help in understanding an aspect of
the molecular mechanisms of sorafenib which have not
been fully elucidated. A recent study indicates that sorafe-
nib significantly altered expression levels of 826 and 2011
transcripts in HepG2 and Huh7 cells respectively [34], indi-
cating the complexity of the mechanism of action of sorafe-
nib. Further studies on this topic are necessary to make
more effective the use of sorafenib as anti-cancer drug.
Conclusions
Our characterization of the down-regulated profile of miR-
193a in HCC might be helpful to differentiate molecular
subtypes of human hepatocellular carcinoma by matching
the miR-193a expression with some clinical features of pa-
tients. Furthermore, our findings may shed light in defining
a pre-clinical therapeutic schedule for HCC based on the
use of miR-193a and miR-23b given alone or in combin-
ation with sorafenib. Our preliminary observations on the
role of sorafenib in mediating, directly or indirectly, the
down-modulation of c-met expression prompt further
studies to acquire new knowledge on the molecular mech-
anism of action of this drug.
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Figure 6 (See legend on next page.)
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Figure 6 Effects on cellular proliferation and apoptosis of combined treatment with sorafenib and miR-193a/miR-23b in HCC cell lines.
(A) The MTT assay showed that the growth of the HA22T/VGH cells was significantly reduced after the combined treatments of sorafenib plus
miR-193a. *p < 0.05; **p < 0.01, ***p < 0.001, ****p < 0.0001 in a one-way ANOVA followed by Bonferroni correction: for sorafenib alone versus 0.1%
DMSO, for miR alone versus Lipofectamine, for the co-treatments versus Lipofectamine plus 0.1% DMSO. (B-E) The HA22T/VGH cells were
transfected with negative control miRNA or miR-193a and treated with either vehicle (0.1% DMSO) or different concentrations of sorafenib
(5-10-15 μM). Two-way ANOVA followed by Bonferroni correction was used to establish whether significant difference existed between negative
control miRNA transfected cells and miR-193a transfected cells; ***p < 0.001. (F) TUNEL assay in SKHep1C3 cells. The cells transfected with 100 nM
miR-23b or miR-193a and then treated with 5 μM sorafenib showed increased percentages of apoptotic cells (up to 1.95 times those of
cells treated with sorafenib alone). *p < 0.05; **p < 0.01 in a two-way ANOVA followed by Bonferroni correction.
Salvi et al. Molecular Cancer 2013, 12:162 Page 10 of 15
http://www.molecular-cancer.com/content/12/1/162Methods
Cell culture and treatments
SKHep1Clone3 (SKHep1C3), selected from human HCC-
derived cells (SKHep1: ATCC HTB-52), was maintained
in Earle’s MEM (Life Technologies, Carlsbad, CA, USA)
supplemented with 10% foetal bovine serum (Life Tech-
nologies) at 37°C in a 5% CO2 incubator. Differentiated
human HCC-derived cells (HepG2, ATTC HB-8065;
HuH-6) and HA22T⁄VGH undifferentiated HCC-derived
cells were maintained in RPMI-1640 (Life Technologies)
supplemented with 10% foetal bovine serum at 37°C in
a 5% CO2 incubator. The HuH-6 and HA22T/VGH cells
were kindly provided by N. D’Alessandro (University
of Palermo, Italy). Sorafenib [N-(3-trifluoromethyl-4-
chlorophenyl)-N-(4-(2-methylcarbamoylpyridin-4-yl) oxy-
phenyl) urea] was synthesized at Bayer Corporation (West
Haven, CT). This compound was dissolved in 100% DMSO
(Sigma, St. Louis, MO) and diluted with DMEM or MEM
to the desired concentration; a final DMSO concentration
of 0.1% was used for in vitro studies. DMSO was added to
cultures at 0.1% (v/v) as a solvent control.
Transient transfection of HA22T/VGH and SKHep1C3 with
miR-193a
Molecules of double-stranded RNAs that mimic endogen-
ous hsa-miR-193a mature miR (5′-AACUGGCCUACAA
AGUCCCAGU3′), anti-miR-193a were purchased from
Life Technologies. For the experimental validation of
miR-193a as negative uPA regulator, HA22T/VGH and
SKHep1C3 cells were seeded in complete medium at 80%
confluence in a 24-well plate (80,000 cells/well). Then,
24 h after seeding, the cells were transfected into serum-
free RPMI or Earle’s MEM, respectively, with 50 and 100
nM of pre-miR-193a and/or anti-miR-193a using Lipofec-
tamine transfection reagent, according to the manufac-
turer’s instruction (Life Technologies). The transfection
medium was replaced with the complete medium after
24 h. The conditioned media and cell lisates were col-
lected 48 h and 72 h after transfection and quantified for
zymography and western blot analysis.
Western blot and zymography
The media for uPA expression analysis were collected
from cultures of both nontransfected and transfected cells.Constant amounts of proteins were loaded (Additional
file 6), under non-reducing conditions, on a Novex NuPAGE
(4–12%) Bis/Tris gel (Invitrogen), or on an 8% SDS
polyacrylamide gel, which was blotted onto a nitrocel-
lulose membrane (NM). NMs were immunoreacted using
rabbit anti-human uPA (1:1000 in 1% BSA) and alkaline
phosphatase-conjugated anti-rabbit IgG (1:7500 in 0.3%
BSA); for zymography, NMs were overlayed onto casein
agar containing 2 μg/mL human plasminogen (Technoclone
GmbH, Vienna, Austria) to evaluate uPA activity. To
evaluate c-met and GAPDH expression in the HA22T/
VGH untreated and treated cells with 5-10-15 μM sorafe-
nib, the cell extracts were collected from 24 h and 48 h
cultures by adding 0.05% SDS. Constant amounts of pro-
teins were loaded, under reducing conditions, on a Novex
NuPAGE (4–12%) Bis/Tris gel or on an 8% SDS polyacryl-
amide gel, and were then transferred to NMs. The blots
were immunoreacted using rabbit anti-human c-met (1:1000
in 0.3% BSA) and rabbit anti-human p-c-met, (Y1003)
(1:1000 in 0.3% BSA), alkaline phosphatase-conjugated
anti-rabbit IgG secondary antibody (1:7500 in 0.3% BSA),
or mouse monoclonal antibodies anti-GAPDH (1:300 in
1% BSA) and alkaline phosphatase-conjugated anti-mouse
IgG secondary antibody (1:7500 in 0.3% BSA). The results
of the immunoreaction were detected with Nitroblue tetra-
zolium and bromochloroindolyl phosphate (Promega). The
bands corresponding to c-met (170 and 145 kDa), uPA and
GAPDH were scanned and analyzed using a digital system
(Gel-Pro Analyzer), and the integrated optical density
(IOD) values were expressed in pixels.
Cell proliferation assays
The cellular proliferation was analysed using the CellTiter
96 Aqueous One Solution reagent (Promega, San Diego,
CA, USA) after the treatment with sorafenib and/or
pre-miR-193a, pre-miR precursor negative control #1
(Life Technologies) and anti-miR-193a transfections.
The cells were seeded in 96-well plates (5 replicates
for each experimental condition) at a density of 4 ×
103 cells/well in a complete cultured medium and 15 μl/
well of sterile CellTiter reagent was added at the estab-
lished time after transfection and/or sorafenib treat-
ments. The plates were measured 2 h after CellTiter
addition using a microplate reader. The absorbance values
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Figure 7 (See legend on next page.)
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Figure 7 Effects of sorafenib on c-met protein expression levels. (A) c-met copy number analysis in the 4 HCC cell lines considered and
comparison with the highest percentage of inhibition of proliferation observed after sorafenib treatments. (B) Western blot and densitometric
analysis of c-met, p-c-met (Y1003) and GAPDH in the HA22T/VGH and HepG2 cells treated with sorafenib *p < 0.05; **p < 0.01 versus HA22T/VGH
or HepG2 in a t-Test analysis for unpaired comparison.
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ing cells in the culture.
In situ cell death
The effects of sorafenib on apoptosis in miR-193a- and
miR-23b [23] transfected or non transfected HCC cells
were measured using the TUNEL assay (terminal deoxy-
nucleotidyl transferase dUTP nick end labeling; Roche
Molecular Biochemicals). SKHep1C3 cells were seeded
on 13 mm-diameter glass coverslips in 24-well plates
(30,000cells/well) and after 24 h the cells were trans-
fected with 100 nM miR-193a or 100 nM miR-23b; after
24 h the media were replaced and 5 µM sorafenib was
added for 24 h. Cell death was detected in situ by en-
zymatic labelling of DNA strand breaks using TUNEL,
according to the manufacturer’s instructions. Briefly, the
DNA end-labelling reaction was performed using terminal
deoxynucleotidyl transferase (TdT) and tetramethylrhoda-
mined UTP (TMR-dUTP), followed by direct analysis
of fluorescent cells. Positive controls were obtained by
treating cells with 7 U/ml DNase for 10 min at room
temperature. Then, the nuclei of the cells were coun-
terstained with 4′, 6-Diamidino-2-Phenylindole (DAPI):
the samples were then analyzed on a fluorescence micro-
scope under 20× magnification. The percentage of TUNEL-
immunostained nuclei (TUNEL labelling index) was calcu-
lated in each sample using the formula: number of labelled
nuclei/total number (labelled + unlabelled) of nuclei × 100.
Measurements were carried out using ImageJ 1.45S soft-
ware. This program allows the user to count random fields
(4 random fields were photographed for each sample and
4 measurements were taken for each picture both for
TMR and DAPI staining to ensure that the percentage of
apoptotic cells are representative of the entire sample).
Luciferase reporter assays
The human 3′ untranslated region (3′UTR) uPA mRNA
(937 bp) were PCR-amplified from cDNA of SKHep1C3
cells, using primers containing flanking XbaI recognition
sequences (Fw: 5′-GCTCTAGACTGAGGGTCCCCAG
GGAG-3′; Rev: 5′-GCTCTAGATTCATCAGAAAAAT
CACATTTTATTG -3′). PCRs were performed using PFU
Taq polymerase (Promega, San Diego, CA, USA) with
proofreading activity. The PCR products were ligated in
the XbaI restriction site downstream of the Renilla lucif-
erase coding region of the pGL4.71 vector (Promega), in
which the simian virus 40 promoter region from the
pGL3-Promoter vector (Promega) had been previouslycloned to obtain the pGL4.71P plasmid. The correct
orientation of the insert was verified by sequencing.
HA22T/VGH cells were seeded at a confluency of
60–80%; 24 h after seeding the cells were transfected
with 0-25-50 nM pre-miR-193a and were then trans-
fected with the luciferase reporter constructs (0.5 μg)
48 h after seeding using Lipofectamine 2000 transfec-
tion reagents according to the manufacturer’s instruction.
Seventy-two hours after seeding, the cells were washed
with NaCl/Pi and lysed with passive lysis buffer (Promega,
San Diego, CA, USA), and the firefly luciferase (f-luc)
and Renilla luciferase (r-luc) activities were determined
using the dual-luciferase reporter assay system (Promega)
and a luminometer. The relative reporter activity was
obtained through normalization to the f-luc activity.
To verify which putative binding site was recognized by
miR-193a, two double-strand oligonucleotides containing
flanking restriction sequences for the enzymes XbaI and
DraI and the 2 putative binding sites were cloned into the
pmiRGLO Dual-Luciferase miRNA Target expression
vector. The sequences of the oligonucleotides were the
following: for site 1: TOP-S1 5′-AAAGCCCAGACCC
CTCTGGCCAGGATGGAGGGGT-3′; BOTTOM-S1 5′-
CTAGACCCCTCCATCCTGGCCAGAGGGGTCTGGG
CTTT-3′; for site 2: TOP-S2 5′-AAATCCCTTTCTT
GGCCAGTTATCCCTTCCTTTT-3′, BOTTOM-S2 5′-
CTAGAAAAGGAAGGGATAACTGGCCAAGAAAGG
GATTT-3′. The plasmid was first linearized with the
restriction enzymes XbaI and DraI and the annealed
oligonucleotides were cloned downstream to the firefly
luciferase CDS. The plasmids expressing the site 1 and site
2 were named pmiRGLO uPA S1 and pmiRGLO uPA S2
respectively, and the control plasmids with the corre-
sponding sequences cloned in antisense orientations were
called pmiRGLO uPA AS1 and pmiRGLO uPA AS2. The
empty plasmid was named pmiRGLO. Firefly luciferase
activity was used as the primary reporter to monitor the
regulation of miR-193a and Renilla luciferase acted as a
control reporter for normalization. The constructs were
co-transfected into HA22T/VGH and SKHep1C3 cells
with 0, 50, 75, 100 nM pre-miR193a and the evaluation of
luciferase activity was performed as decribed above.
Tissues and clinicopathological features of HCC and
real-time evaluation of mature miR-193a expression in
tumoural and peri-tumoural (PT) human tissues
All human HCC samples (n = 39) as well as the corre-
sponding PT non-tumour samples (resected 1–2 cm from
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for pathological examination. Each biopsy specimen was
obtained with the patient’s informed consent under stand-
ard conditions of sampling and processing [23]. Each spe-
cimen was determined to be HCC or PT by pathological
examination. In this study, 39 HCC subjects underwent
surgical resection. The subjects consisted of 26 men and
13 women (38 Italian and 1 Chinese) ranging from 38 to
82 years of age (mean age: 67.8 ± 9.06 years). The subjects
did not have any apparent distant metastases, and none
had been previously treated for HCC. We have subdivided
the cases on the basis of presence or absence of liver cir-
rhosis (25 HCC with cirrhosis, 14 HCC without cirrhosis);
the patients were tested for the presence of the hepatitis B
virus (HBV) and hepatitis C (HCV) virus. Fifteen patients
were positive for HCV, 9 were positive for HBV, 4 were
positive for both HBV and HCV, and 6 were negative
for both HBV and HCV; for 5 patients no informa-
tion was available (Additional file 1). The total RNA
from tissue samples was isolated using TRIzol reagent
(Invitrogen), according to the manufacturer’s instruc-
tions. To measure the amount of mature miR-193a, a two-
step TaqMan real-time PCR analysis was performed, using
primers and probes obtained from Life Technologies-
Applied Biosystems. In a reaction volume of 15 μl, cDNA
was synthesized from 50 ng of total RNA, using reverse
transcriptase and the stem–loop primer for miR-193a
(Applied Biosystems; PN 4427975) or RNU66 (internal
control; Applied Biosystems; PN 4373382) contained in
the TaqMan MicroRNA Reverse Transcription kit (Applied
Biosystems, Foster, CA, USA). The reverse transcriptase
reaction was performed by incubating the samples at 16°C
for 30 min, 42°C for 30 min, and 85°C for 5 min. The PCR
reaction (20 μL) contained 1.3 μL of reverse transcriptase
product, 10 μL of Taq-Man 2× Universal PCR Master Mix,
and 1 μL of the appropriate TaqMan MicroRNA Assay
(20×) containing primers and probes for the miR of inter-
est. The PCR mixtures were incubated at 95°C for 10 min,
and this was followed by 40 cycles of 95°C for 15 s and
60°C for 60 s. PCR reactions were performed in triplicate
using a 7500 real time PCR system. The expression of
miR-193a was based on the ΔΔCT method, using RNU66
as an internal control. For each case the ratio (R) between
the relative levels in HCC and those in PT was assessed.
The level of expression of the miRNAs was considered
to be decreased for a R value <0.7 and increased for
a R value >1.3. A value between 0.7 and 1.3 was de-
fined as having no change in expression level [29].
c-met copy number evaluation
DNA from HCC cell lines was extracted using TRizol
reagent, according to the manufacturer’s instructions.
Quadruplicates of each sample using 20 ng of genomic
DNA per sample were amplified using four differentTaqMan probes (Applied Biosystems, Life Technologies)
spanning the entire c-met gene and chosen within the
exon 2 (hs 01375065-cn), intron 5 (hs 04992567-cn), exon
8 (hs 02633538-cn) and exon 21 (hs 01932765-cn). The
PCR mixtures were incubated at 95°C for 10 min and this
was followed by 40 cycles at 95°C for 15 s and 60°C for
60 s. The method of relative quantification was used to
determine the relative copy number of the c-met in each
DNA sample, normalized to the known copy number of
the reference gene RNase P. The RNase P probe was run
together with each c-met probe using duplex real-time
PCR (Applied Biosystem 7500).
Statistical analysis
Each experiment was carried out at least twice. Histo-
grams represent the mean values, and bars indicate stand-
ard errors (SE) of the mean. For the data shown in
Figures 2, 3, 4 and 7 statistical analysis (Student’s t-test)
was performed with kyplot, version 2.0 beta 13 (KyensLab
Incorporated, Tokjo, Japan; www.kyenslab.com). For the
data shown in Figures 5 and 6 statistical analysis (one way
ANOVA with Bonferroni correction; two way ANOVA
with Bonferroni correction) was performed with GraphPad
Prism 6.0 (GraphPad Softwares Inc, San Diego, CA, USA).
Data were considered significant when P ≤ 0.05.
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.Additional files
Additional file 1: Table S1. Clinical and phatological characteristics of
the studied population.
Additional file 2: miR-193a expression level detected by real-time
PCR in tissues from biopsy specimens from patients affected by
HCC. The graph indicates the R (RQHCC/RQPT) corresponding to the
human sample tested. The histograms are ordinated by increasing R.
The background disease are also indicated (LC, liver cirrhosis; O, other
background disease i.e., B/C viral hepatitis, steatosis). The R values and
the case number (LV) are listed under the graph.
Additional file 3: Normal distribution of the R values (RQHCC/RQPT)
of miR-193a detected by real-time PCR in tissues from biopsy
specimens from patients affected by HCC. The black curve indicates
the normal distribution of R in all cases tested; the dashed black and grey
curves refer to the HCC samples with, respectively, the presence or
absence of liver cirrhosis as background disease.
Additional file 4: miR-193a expression level detected by real-time
PCR in tissues from biopsy specimens from patients affected by
HCC with the absence (A) or presence (B) of liver cirrhosis as
background disease. The graph indicates the R (RQHCC/RQPT)
corresponding to the human sample tested. The histograms are
ordinated by increasing R. The background diseases are also indicated
(LC, liver cirrhosis; O, other background disease i.e., B/C viral hepatitis,
steatosis). The R values and the case number (LV) are listed under the
graph.
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non-cirrhotic HCCs on the basis of the type of hepatitis virus infection.
HBV (n=5); HCV (n=5); HBV/HCV (n=0); -/- (n=2). The miR-193a is
down-modulated in the HCC patients with and without cirrhosis subdivided
on the basis of the HCV virus infection (n=15). The mean R value
was 0.604±0,14 which was significantly different from the expected
value=1, p=0.0167.
Additional file 6: Loading controls relative to Figures 2A, B, A and
Figure 3B. Coomassie staining of proteins loaded on polyacrylamide gels
8% (panel A, left) and 4-12% pre-cast gels (panel A, right and panel B).
The staining highlights constant amounts of total proteins loaded for
each gel.
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